Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation

Wang, Xiaoning; Ren, Juan; Liang, Xiao; He, Pengcheng

doi:10.1080/16078454.2021.2003071

Cited by 8 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current data describing the use of BIO/PEG in patients with MM post-ASCT are scarce. A 2021 study by Wang and colleagues reported that among patients with MM who underwent ASCT, the mean time to neutrophil engraftment was 8.72 days in patients treated with BIO/PEG versus 9.87 days in those who received BIO/G-CSF [ 24 ]. Similarly, a comparative study by Vanstraelen and colleagues reported a median time to neutrophil engraftment of 8 and 9 days in patients treated with BIO/PEG and BIO/G-CSF, respectively [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

et al. 2023

View full text Add to dashboard Cite

Multiple myeloma (MM) is the main indication for autologous stem cell transplantation (ASCT). Novel supportive therapies (e.g., granulocyte colony-stimulating factor) have significantly improved post-ASCT-related mortality; however, data on biosimilar pegfilgrastim-bmez (BIO/PEG) in this setting is lacking. This prospective cohort study compared Italian patients with MM who received BIO/PEG post-ASCT with data collected retrospectively from historical control groups from the same center who received either filgrastim-sndz (BIO/G-CSF) or pegfilgrastim (PEG; originator). The primary endpoint was time to neutrophil engraftment (three consecutive days with an absolute neutrophil count ≥ 0.5 × 109/L). Secondary endpoints included incidence and duration of febrile neutropenia (FN). Of the 231 patients included, 73 were treated with PEG, 102 with BIO/G-CSF, and 56 with BIO/PEG. Median age was 60 years and 57.1% were male. Neutrophil engraftment was reached after a median of 10 days in the BIO/PEG and PEG groups and 11 days in the BIO/G-CSF group. Among patients who achieved neutrophil engraftment earlier than this (i.e., day 9), 58% (29/50) were on PEG; of those who achieved it later (i.e., day 11), 80.8% (59/73) were on BIO/G-CSF. FN incidence was higher with BIO/G-CSF (61.4%) versus PEG (52.1%) or BIO/PEG (37.5%) (p = 0.02 among groups). Patients on BIO/PEG had less frequent grade 2–3 diarrhea (5.5%) compared with BIO/G-CSF (22.5%) or PEG (21.9%); grade 2–3 mucositis was most frequent in the BIO/G-CSF group. In conclusion, pegfilgrastim and its biosimilar displayed an advantageous efficacy and safety profile compared with biosimilar filgrastim in patients with MM post-ASCT.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Data about biosimilar Peg-Filgrastim are still scarce in this context. Recently, some studies have been published, all together showing a slightly superiority of biosimilar pegylated formulations over the short-acting G-CSFs in myeloma and lymphoma patients undergoing ASCT [ 11 , 21 ]. The physiological reason for the better performance of pegylated G-CSF formulation can be found looking at the pharmacokinetics of Peg-filgrastim.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim

Marchesi,

Terrenato,

Papa

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Data about biosimilar Peg-filgrastim (bioPEG) in autologous stem cell transplant (ASCT) are still scarce. The aim of this study has been to assess efficacy and safety of bioPEG among lymphoma and myeloma patients undergoing ASCT, comparing these data with historical controls receiving other G-CSFs. Furthermore, an economic evaluation has been included to estimate the savings by using bioPEG. This is a prospective cohort study comparing lymphoma and myeloma patients undergoing ASCT and receiving bioPEG (n = 73) with three historical consecutive cohorts collected retrospectively who received other G-CSFs (Lenograstim — Leno — n = 101, biosimilar Filgrastim — bioFIL n = 392, and originator Peg-filgrastim — oriPEG n = 60). We observed a significantly shorter time to neutrophils and platelet engraftment (p < 0.001) in patients treated with bioPEG and oriPEG. Moreover, patients who received bioPEG showed a shorter hospitalization time (p < 0.001) and a lower transfusion need (p < 0.001). We did not observe any significant difference in terms of transplant-related mortality, mucositis, and diarrhea among the four groups. No serious adverse events were associated with bioPEG. Similar data were obtained after running a stratified analysis for lymphomas and myeloma separately conducted by using a propensity score matching. The average total cost per patient of bioPEG was € 18218.9 compared to € 23707.8, € 20677.3 and € 19754.9 of Leno, oriPEG, and bioFIL, respectively. In conclusion, bioPEG seems to be as effective as the originator and more effective than short-acting G-CSFs in terms of post-transplant engraftment in myeloma and lymphoma patients undergoing ASCT. Moreover, bioPEG was cost-effective when compared with the other G-CSFs.

show abstract

“…Antifungal, analgesic, or anticoagulant treatments for patients with relapse were found to be signi cant compared with patients in remission (Table 3). As a result of the study examining the prophylaxis of febrile neutropenia in patients with lymphoma undergoing autologous SCT, it was reported that the use of G-CSF was bene cial in terms of infection risks that may occur in patients and contributes to the reduction of the burden of other symptoms [27]. It was stated that febrile neutropenia was among the most common reasons for hospitalization in patients undergoing autologous SCT and that the use of antibiotics increased patients' quality of life and reduced hospital admissions [28].…”

Section: Discussionmentioning

confidence: 99%

A retrospective study of treatment and outcomes of patients with lymphoma undergoing hematopoietic stem cell transplantation

Sezgi̇n

Bektaş

2022

Preprint

View full text Add to dashboard Cite

PurposeEarly evaluation of symptoms and taking appropriate preventive measures can improve outcomes for patients with lymphoma undergoing hematopoietic stem cell transplantation. This study was conducted to examine the treatment and outcomes of patients with lymphoma undergoing hematopoietic stem cell transplantation. MethodsPatients with lymphoma (n=64) undergoing SCT at a university hospital between June 15, 2018 and June 15, 2020 were selected for retrospective study. The medical treatments of patients were obtained from the records on the Hospital Information Management System database. The study was reported following the STROBE checklist. Standard deviation, arithmetic mean, frequency, percentage test, t-test, chi-square, Fisher’s exact test, Mann-Whitney U test, Independent t-test, and multivariate logistic regression analysis were used to analyze the data.ResultsThe mean age of patients was 48.25±16.93. Although relapse developed in 26 patients with lymphoma, remission was achieved in 38 patients. The incidence of skin graft-versus-host disease (GVHD) symptoms in patients with relapse was found to be significantly higher than in patients in remission. The most common symptoms seen in patients undergoing stem cell transplantation were oral mucositis, febrile neutropenia, and anemia. Most patients were found to receive oral care, antibiotic treatment, and granulocyte-colony stimulating factor (G-CSF) treatment following SCT. ConclusionsPatients experienced severe symptoms due to HSCT, and necessary treatment was applied for the symptoms. Further clinical studies must determine the symptoms and patient outcomes associated with SCT.

show abstract

Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation

Cited by 8 publications

References 28 publications

Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim

A retrospective study of treatment and outcomes of patients with lymphoma undergoing hematopoietic stem cell transplantation

Contact Info

Product

Resources

About